OncoCyte (OCX) to Release Quarterly Earnings on Wednesday

OncoCyte (NASDAQ:OCXGet Free Report) is set to release its earnings data after the market closes on Wednesday, May 15th. Analysts expect OncoCyte to post earnings of ($0.82) per share for the quarter.

OncoCyte Stock Down 0.3 %

OncoCyte stock opened at $2.88 on Tuesday. OncoCyte has a 52 week low of $2.08 and a 52 week high of $5.60. The business’s 50-day moving average price is $2.83 and its 200 day moving average price is $3.02.

Analyst Ratings Changes

Several research firms have recently weighed in on OCX. StockNews.com started coverage on shares of OncoCyte in a report on Sunday. They set a “sell” rating for the company. Stephens reaffirmed an “equal weight” rating and issued a $4.00 price objective on shares of OncoCyte in a report on Wednesday, April 17th. Needham & Company LLC increased their target price on shares of OncoCyte from $3.60 to $4.25 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Benchmark restated a “speculative buy” rating and issued a $5.00 price target on shares of OncoCyte in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.06.

Read Our Latest Stock Report on OCX

Insider Activity

In other news, Director Andrew Arno bought 33,898 shares of OncoCyte stock in a transaction on Thursday, April 11th. The stock was acquired at an average price of $2.95 per share, with a total value of $99,999.10. Following the completion of the acquisition, the director now directly owns 69,054 shares of the company’s stock, valued at $203,709.30. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other OncoCyte news, Director Andrew Arno acquired 33,898 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was bought at an average price of $2.95 per share, with a total value of $99,999.10. Following the purchase, the director now owns 69,054 shares in the company, valued at $203,709.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the firm’s stock in a transaction on Thursday, April 11th. The stock was acquired at an average cost of $2.92 per share, for a total transaction of $7,066,400.00. Following the completion of the purchase, the insider now directly owns 4,929,066 shares in the company, valued at $14,392,872.72. The disclosure for this purchase can be found here. Insiders have purchased a total of 2,457,288 shares of company stock worth $7,176,400 over the last 90 days. 1.94% of the stock is currently owned by company insiders.

About OncoCyte

(Get Free Report)

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.

Featured Articles

Earnings History for OncoCyte (NASDAQ:OCX)

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.